Cytosorbents (CTSO) Free Cash Flow (2010 - 2026)

Cytosorbents has reported Free Cash Flow for 17 years, with the latest figure at -$1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 66.18% year-over-year to -$1.2 million; the trailing twelve-month figure through Mar 2026 stood at -$10.2 million (up 22.99% YoY), and the FY2025 full-year result was -$12.5 million, up 14.76% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$1.2 million, up from -$4.9 million in the prior quarter.
• The five-year high for Free Cash Flow was -$1.2 million in Q1 2026, with the low at -$11.1 million in Q4 2022.
• Historically, Free Cash Flow has averaged -$5.0 million across 5 years, with a median of -$4.8 million in 2024.
• Annual changes were most pronounced in 2022 — Free Cash Flow sank 294.31% — and 2023, when it surged 69.69%.
• Cytosorbents' Free Cash Flow stood at -$11.1 million in 2022, then jumped by 41.66% to -$6.5 million in 2023, then soared by 62.94% to -$2.4 million in 2024, then slumped by 104.69% to -$4.9 million in 2025, then surged by 76.22% to -$1.2 million in 2026.
• The last three Free Cash Flow figures came in at -$1.2 million (Q1 2026), -$4.9 million (Q4 2025), and -$2.6 million (Q3 2025), per Business Quant data.